Biogen Inc. BIIB
249.59 USD +2.46 (+1.00%)
Regular-session close
249.28 -0.31 -0.12%
After hours · Nov 20, 7:41 PM ET
248.04 Day range 253.00
164.42 52-week range 254.87
- YTD
- +41.82%
- 1 year
- +48.41%
News
benzinga.com Eisai And Biogen Present Findings From Analysis Of Lecanemab-Irmb Treatment And α-Syn Co-Pathology In Cerebrospinal Fluid Substudy Of Clarity AD In Early Alzheimer’s Disease, At CTAD Conference Lecanemab showed favorable results on clinical assessment scores at 18 months, including among individuals with early Alzheimer’s disease (AD) who were α-synuclein positive, a subgroup associated…
prnewswire.com Clarity AD CSF Substudy Findings on Lecanemab Treatment and α-Synuclein Co-Pathology Presented at CTAD 2026 Lecanemab showed favorable results on clinical assessment scores at 18 months, including among individuals with early Alzheimer's disease (AD) who were α-synuclein positive, a subgroup associated…
defenseworld.net Biogen Prepares Joint Lupus Trial Results as It Targets First Revenue Growth Since 2019 Biogen (NASDAQ: BIIB) expects to announce results from two systemic lupus erythematosus trials together in a press release, as the company prepares for a series of pipeline readouts and seeks to…
defenseworld.net Biogen Inc. $BIIB Shares Bought by Bogart Wealth LLC Bogart Wealth LLC increased its position in shares of Biogen Inc. (NASDAQ: BIIB) by 1,367.7% during the third quarter, according to the company in its most recent disclosure with the Securities and…
prnewswire.com New Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026 Largest analysis of LEQEMBI LEADER study reported to date includes findings on amyloid clearance in routine clinical practice, delayed progression to moderate or severe AD, expanded subcutaneous…
benzinga.com Biogen Reports Two-Year Data Showing Diranersen Slows Early Alzheimer's Decline Biogen reports two-year Phase 2 CELIA data showing diranersen slows clinical decline and cuts tau biomarkers in early Alzheimer's disease.
marketbeat.com Biogen Prepares Joint Lupus Trial Results as It Targets First Revenue Growth Since 2019 Biogen NASDAQ: BIIB expects to announce results from two systemic lupus erythematosus trials together in a press release, as the company prepares for a series of pipeline readouts and seeks to return…
reuters.com Biogen's anti-tau Alzheimer's drug benefits increase at 2 years Biogen's anti-tau Alzheimer's drug benefits increase at 2 years
fool.com Biogen: 3 Key Takeaways for Long-Term Investors Total third quarter core pharmaceutical revenue reached $2 billion. Growth portfolio revenue rose 49% year over year in Q3.
globenewswire.com Biogen's Diranersen Demonstrates Increasing Clinical Benefit at Two Years in Early Alzheimer's Disease CAMBRIDGE, Mass., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data from the Phase 2 CELIA study showing increasing clinical benefit of diranersen, an…
seekingalpha.com Biogen Inc. (BIIB) Presents at Jefferies Global Healthcare Conference 2026 Transcript Biogen Inc. (BIIB) Presents at Jefferies Global Healthcare Conference 2026 Transcript
globenewswire.com The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of publicly-traded Biogen Inc. common stock– BIIB BOSTON, Nov. 17, 2026 (GLOBE NEWSWIRE) -- The Rosen Law Firm, P.A. announces that the United States District Court for the District of Massachusetts has approved the following announcement of a…benzinga.com Reported Earlier, Lecanemab Five-Year Clarity AD Data: 36% Lower Relative Risk Of Disease-Stage Progression Vs. ADNI, 62% Of Low-Tau Patients Improved On CDR-SB, Consistent Safety Profile, Per Eisai And Biogen Benefits of continuous lecanemab treatment in early Alzheimer’s disease accrue over timeLecanemab reduced the relative risk of progression to the next stage of disease by 36% vs. ADNI62% of patients…
prnewswire.com New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026 Benefits of continuous lecanemab treatment in early Alzheimer's disease accrue over time Lecanemab reduced the relative risk of progression to the next stage of disease by 36% vs. ADNI 62% of…
benzinga.com Biotech ETFs Brace for FDA Showdown: Two Drug Decisions Could Test Investor Sentiment XBI and IBB lagged SPY and QQQ as two FDA decisions and fresh Alzheimer's and obesity-drug data put biotech ETFs in focus.
businesswire.com TRIMTECH Therapeutics Enters Strategic Research Collaboration With Biogen to Advance Small Molecule Degraders for Neurodegenerative Disease CAMBRIDGE, England--(BUSINESS WIRE)--TRIMTECH Therapeutics, a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with…
fool.com Which Healthcare ETF Is Best for the Long Term: State Street’s XPH or Invesco’s PBE? Lower fees and a steadier beta set one healthcare ETF apart, while the rival fund's richer dividend could sway income-focused investors.benzinga.com Piper Sandler Reiterates Overweight on Biogen, Raises Price Target to $305 Piper Sandler analyst David Amsellem reiterates Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $245 to $305.
benzinga.com UCB And Biogen Report Dapirolizumab Pegol Plus SOC Associated With Higher Response Versus Placebo On Novel TRM-SLE And Greater Sustained Low Disease Activity In Post-Hoc Phase 3 PHOENYCS GO Analyses Dapirolizumab pegol (DZP) associated with higher response rates using the novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): A post-hoc analysis applying TRM-SLE to the DZP…
benzinga.com Biogen Canada Announces Broad Private Drug Plan Coverage For ZURZUVAE, Expanding Access For Eligible Patients With Postpartum Depression In Adults Following Childbirth Most national private drug plans now provide coverage for ZURZUVAE™, broadening access for eligible Canadian patients with private insurance coverage.Toronto, November 5, 2026 — Biogen Canada Inc.…
benzinga.com Guggenheim Maintains Buy on Biogen, Raises Price Target to $300 Guggenheim analyst Yatin Suneja maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $280 to $300.
benzinga.com Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday Analysts upgraded MHK and CRWD, downgraded PFSI, cut ABOS’s target, and raised targets for NRXP, REGN and NTSK.benzinga.com HC Wainwright & Co. Maintains Buy on Biogen, Raises Price Target to $270 HC Wainwright & Co. analyst Ananda Ghosh maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $251 to $270.
benzinga.com Incyte To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday Analysts raised targets for Cheniere and Incyte, while cutting Stryker, Roblox, Intel and Honeywell; Bright Horizons was downgraded.benzinga.com Canaccord Genuity Maintains Buy on Biogen, Raises Price Target to $272 Canaccord Genuity analyst Sumant Kulkarni maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $248 to $272.
benzinga.com Argus Research Upgrades Biogen to Buy, Announces $280 Price Target Argus Research analyst Jasper Hellweg upgrades Biogen (NASDAQ:BIIB) from Hold to Buy and announces $280 price target.
benzinga.com RBC Capital Maintains Outperform on Biogen, Raises Price Target to $272 RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $256 to $272.
benzinga.com Morgan Stanley Maintains Equal-Weight on Biogen, Raises Price Target to $238 Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from $231 to $238.
benzinga.com TD Cowen Maintains Buy on Biogen, Raises Price Target to $260 TD Cowen analyst Phil Nadeau maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $250 to $260.
benzinga.com Wedbush Maintains Neutral on Biogen, Raises Price Target to $225 Wedbush analyst Laura Chico maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $212 to $225.
benzinga.com Truist Securities Reiterates Buy on Biogen, Raises Price Target to $260 Truist Securities analyst Danielle Brill reiterates Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $235 to $260.
benzinga.com Microsoft To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Thursday Analysts raised targets for Microsoft, VF, Glaukos, Hilton, AxoGen and Brinker; Renasant’s target was cut and its rating downgraded.
benzinga.com These Analysts Increase Their Forecasts On Biogen After Upbeat Q3 Results Biogen beats Q3 estimates, narrows FY2026 EPS outlook, and sees analysts raise price targets to $290; shares dip 0.3% premarket.benzinga.com Baird Maintains Outperform on Biogen, Raises Price Target to $290 Baird analyst Brian Skorney maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $250 to $290.
benzinga.com Needham Maintains Buy on Biogen, Raises Price Target to $290 Needham analyst Ami Fadia maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $256 to $290.
benzinga.com Barclays Maintains Equal-Weight on Biogen, Raises Price Target to $230 Barclays analyst Emily Field maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from $200 to $230.
benzinga.com Biogen Q3 2026 Earnings Call Transcript Biogen (NASDAQ:BIIB) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…benzinga.com CORRECTION: Biogen Narrows FY2026 Adj EPS Guidance from $15.85-$16.85 to $15.95-$16.75 vs $12.36 Est Biogen (NASDAQ:BIIB) narrows FY2026 Adj EPS guidance from $15.85-$16.85 to $15.95-$16.75 vs $12.36 analyst estimate..
benzinga.com Biogen Raises FY2026 GAAP EPS Guidance from $12.00-$13.00 to $12.20-$13.00 vs $5.84 Est Biogen (NASDAQ:BIIB) lowers FY2026 Adj EPS guidance from $15.25-$16.25 to $12.20-$13.00 vs $12.36 analyst estimate..
benzinga.com B of A Securities Maintains Neutral on Biogen, Raises Price Target to $244 B of A Securities analyst Jason Zemansky maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $219 to $244.
benzinga.com TD Cowen Maintains Buy on Biogen, Raises Price Target to $250 TD Cowen analyst Phil Nadeau maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $225 to $250.
finance.yahoo.com Cerebras Systems Inc. (CBRS) Cerebras reported strong third-quarter growth, led by cloud revenue, and expanded relationships with Microsoft, Oracle, AWS, and OpenAI. The company raised its 2026 core revenue outlook, but delivery…
finance.yahoo.com Swarmer, Inc (SWMR) Swarmer is shifting from selling autonomy software to providing complete defense systems through ground vehicles, drones, and air-defense products. The company completed its Vataga Drone ...
fidelity.co.uk Biogen Inc (BIIB) Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and ...
seekingalpha.com Biogen: Why I'm Still Bullish Despite Market Turmoil Biogen Inc. is rated a Buy, as Leqembi Q3 sales rise 66.9% year over year to $202 million and progression risk falls 49% ...
rttnews.com Weekly Buzz: SNY, REGN Score Approvals; MIST Cuts Costs; ABBV, LLY, JNJ Strike Deals Regeneron Pharmaceuticals ( REGN) secured FDA approval for Livsayis (cemdisiran), the first siRNA therapy for adults with ...
ad-hoc-news.de Biogen stock: Lecanemab data show benefit in alpha-synuclein group Biogen stock gets fresh clinical support from lecanemab data presented at CTAD 2026. The subgroup showed slower decline than ...
crowdfundinsider.com Anthropic’s ($ANT) First Trading Day Includes Onchain Access via Securitize on Solana Anthropic (NASDAQ:ANT), the artificial intelligence firm behind the Claude models, completed its highly anticipated initial public offering on the Nasdaq ...
msn.com Are Wall Street analysts predicting Biogen stock will climb or sink? Headquartered in Cambridge, Massachusetts, Biogen Inc. (BIIB) is a biotechnology company focused on developing and ...
marketscreener.com Mizuho Securities Adjusts Biogen Price Target to $271 From $241, Maintains Outperform Rating Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales ...
